Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,061Revenue $M262Net Margin (%)-7.7Z-Score18.9
Enterprise Value $M955EPS $-0.4Operating Margin %-7.3F-Score4
P/E(ttm))0Cash Flow Per Share $0.5Pre-tax Margin (%)-7.5Higher ROA y-yN
Price/Book7.310-y EBITDA Growth Rate %0Quick Ratio4.5Cash flow > EarningsY
Price/Sales3.95-y EBITDA Growth Rate %0Current Ratio4.5Lower Leverage y-yY
Price/Cash Flow54.0y-y EBITDA Growth Rate %-275.0ROA % (ttm)-12.0Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-14.7Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M31.5ROI % (ttm)1.3Gross Margin Increase y-yN

Gurus Latest Trades with GHDX

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
GHDXDavid Swensen 2013-03-31 Sold Out -2.8%$26.72 - $29.65
($28.5)
$ 33.6518%Sold Out0
GHDXDavid Swensen 2012-12-31 Buy 2.8%$26.42 - $36.8
($30.13)
$ 33.6512%New holding, 37861 sh.37,861
GHDXDavid Swensen 2011-03-31 Sold Out -0.93%$21.08 - $26.18
($23.29)
$ 33.6544%Sold Out0
GHDXDavid Swensen 2010-12-31 Buy 0.93%$13.18 - $23.52
($17.74)
$ 33.6590%New holding, 38243 sh.38,243
GHDXGeorge Soros 2006-12-31 Sold Out -0.23%$13.85 - $23.89
($17.5)
$ 33.6592%Sold Out0
GHDXGeorge Soros 2006-09-30 Buy 0.23%$11.16 - $14.38
($13)
$ 33.65159%New holding, 236371 sh.236,371
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

GHDX is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


GHDX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Popovits Kimberly JPresident and CEO 2014-10-13Sell3,000$30.789.32 view
Cole G BradleyCOO 2014-10-08Sell4,000$28.7716.96 view
Popovits Kimberly JPresident and CEO 2014-09-11Sell3,000$29.8212.84 view
Cole G BradleyCOO 2014-09-08Sell4,700$30.0911.83 view
Shak StevenEVP of R&D 2014-08-14Sell13,348$27.3622.99 view
Popovits Kimberly JPresident and CEO 2014-08-12Sell3,000$26.0729.08 view
Popovits Kimberly JPresident and CEO 2014-07-14Sell3,000$26.5926.55 view
Cole G BradleyCOO 2014-07-08Sell2,300$27.0524.4 view
Shak StevenEVP of R&D 2014-07-01Sell7,000$2724.63 view
Popovits Kimberly JPresident and CEO 2014-06-12Sell3,000$26.128.93 view

Press Releases about GHDX :

    Quarterly/Annual Reports about GHDX:

    News about GHDX:

    Articles On GuruFocus.com
    CEO of InVitae Corporation of Genomic Health Inc. Randal W. Scott Sold 30,000 Shares Jul 13 2012 
    Genomic Health Inc. (GHDX) President and CEO Kimberly J Popovits sells 8,000 Shares Mar 16 2011 
    Genomic Health Inc. (GHDX) CFO Dean L Schorno sells 1,000 Shares Mar 16 2011 
    Genomic Health Inc. (GHDX) Executive Chairman Randal W Scott sells 20,000 Shares Mar 14 2011 
    Genomic Health Inc. (GHDX) COO G Bradley Cole sells 2,500 Shares Mar 10 2011 
    Genomic Health Inc. (GHDX) President and CEO Kimberly J Popovits sells 8,000 Shares Feb 16 2011 
    Genomic Health Inc. (GHDX) President and CEO Kimberly J Popovits sells 8,000 Shares Feb 16 2011 
    Genomic Health Inc. (GHDX) CFO Dean L Schorno sells 1,000 Shares Feb 16 2011 
    Genomic Health Inc. (GHDX) Executive Chairman Randal W Scott sells 20,000 Shares Feb 14 2011 
    Genomic Health Inc. (GHDX) President and CEO Kimberly J Popovits sells 8,000 Shares Jan 19 2011 

    More From Other Websites
    Should Genomic Health (GHDX) Be in Your Portfolio Now? Oct 15 2014
    Genomic Health Announces Positive Results from Latest Clinical Validation Study of Oncotype DX® as... Sep 29 2014
    Genomic Health Announces Oral Presentation of Positive Results from Second Large, Independent... Sep 26 2014
    Genomic Health Upbeat on Strong International Performance Sep 25 2014
    New Survey Reveals Alarming Lack of Understanding of Prostate Cancer, Inspires "Your Prostate Your... Sep 24 2014
    Genomic Health Reveals Positive Oncotype DX Test Results Sep 15 2014
    Genomic Health Announces Publication of Colon Cancer Cost-Effectiveness Study in PharmacoEconomics Sep 12 2014
    Genomic Health Announces Presentation of Positive Results from Latest Prostate Cancer Clinical... Sep 09 2014
    GENOMIC HEALTH INC Financials Aug 15 2014
    Genomic Health Raised to Buy on Better-than-Expected Q2 Aug 14 2014
    Genomic Health Q2 Loss Narrower than Expected, Shares Up Aug 11 2014
    GENOMIC HEALTH INC Files SEC form 10-Q, Quarterly Report Aug 08 2014
    Genomic Health to Present at the Canaccord Genuity 34th Annual Growth Conference Aug 08 2014
    GENOMIC HEALTH INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Aug 07 2014
    Genomic Health Announces Second Quarter 2014 Financial Results and Business Progress Aug 07 2014
    Q2 2014 GENOMIC HEALTH INC Earnings Release - After Market Close Aug 07 2014
    Genomic Health Announces Positive Topline Results of Additional, Large Independent Validation Study... Aug 06 2014
    Is a Surprise Coming for Genomic Health (GHDX) This Earnings Season? Aug 06 2014
    Genomic Health to Announce Second Quarter 2014 Financial Results and Host Conference Call on... Jul 31 2014
    3 Health Care Stocks Primed For Big Moves Jul 14 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK